A Phase 1/2 interventional study of Investigational hMPV/RSV vaccine and Investigational hMPV vaccine (monovalent) in Human Metapneumovirus Immunization and Respiratory Syncytial Virus Immunization, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 24 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Respiratory Syncytial Virus Infections by Sanofi — none open to participants now, 2 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Sanofi.
Among the 15 studies in Respiratory Syncytial Virus Infections by Sanofi, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 1/2, and was the 13th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →None of the 15 studies in Respiratory Syncytial Virus Infections by Sanofi is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 6
First in 2011; this study’s year is marked. 5 started in 2024.
This study's enrollment of 1,530 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 310 across the 14 interventional studies, 344 across the 1 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
2 of the studies in Respiratory Syncytial Virus Infections by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06686654Sanofi Pasteur, a Sanofi CompanyStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | 2027-01-18 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Respiratory Syncytial Virus Infections by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older.
The study will also evaluate the safety and immunogenicity of a booster vaccination using a bivalent hMPV/RSV mRNA vaccine candidate (hereafter referred to as RSV+hMPV mRNA vaccine candidate).
Overall, the study is designed to address the following goals:
The study duration is as follows:
-Six months each for the Sentinel and Main Cohorts; up to 12 months for the Expansion Cohort, and 6 additional months for the Booster Cohort
Treatment duration:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 IM injection of investigational hMPV/RSV vaccine formulation A
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation B
Biological: Investigational hMPV/RSV vaccine
1 IM injection of placebo
Biological: Placebo
1 IM injection of investigational hMPV/RSV vaccine formulation C
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation D
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation E
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation F
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation G
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation A
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation B
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation H
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation I
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational hMPV/RSV vaccine formulation J
Biological: Investigational hMPV/RSV vaccine
1 IM injection of placebo
Biological: Placebo
1 IM injection of selected investigational hMPV/RSV vaccine formulation from Group 1-9 of Stage 1 Main Cohort
Biological: Investigational hMPV/RSV vaccine
1 IM injection of investigational RSV monovalent vaccine
Biological: Investigational RSV vaccine (monovalent)
1 IM injection of investigational hMPV monovalent vaccine
Biological: Investigational hMPV vaccine (monovalent)
1 IM injection of licensed RSV vaccine
Biological: Licensed RSV Vaccine
1 IM injection of investigational RSV + hMPV vaccine formulation administered to participants from Group 14 of Expansion Cohort
Biological: Investigational hMPV/RSV vaccine · Biological: Investigational RSV+hMPV vaccine
Investigational hMPV/RSV vaccine administered intramuscularly
Investigational hMPV vaccine (monovalent) administered intramuscularly
Investigational RSV vaccine (monovalent) administered intramuscularly
Licensed RSV vaccine administered intramuscularly
Placebo administered intramuscularly
Investigational RSV+hMPV vaccine administered intramuscularly
Presence of unsolicited immediate systemic adverse events (AEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)
Number of participants reporting immediate unsolicited systemic AEs
Time frame: Within 30 minutes after primary and booster vaccinations
Presence of solicited injection site and systemic reactions (Stage 1 and Stage 2 Expansion and Booster Cohorts)
Number of participants reporting solicited injection site and systemic reactions
Time frame: Up to 7 days after primary and booster vaccinations
Presence of unsolicited AEs (Stage 1 and Stage 2 Expansion and Booster Cohorts)
Number of participants reporting unsolicited AEs
Time frame: Up to 28 days after primary and booster vaccinations
Presence of medically attended AEs (MAAEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)
Number of participants reporting MAAEs
Time frame: Up to 6 months after primary and booster vaccinations
Presence of serious AEs (SAEs) and AEs of special interest (AESIs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)
Number of participants reporting SAEs and AESIs
Time frame: Up to 6 months after primary and booster vaccinations
Presence of related SAEs, related AESIs, and fatal SAEs (regardless of causality) (Stage 1 and Stage 2 Expansion and Booster Cohorts)
Number of participants reporting related SAEs, related AESIs, and fatal SAEs
Time frame: Throughout the duration of the study (up to approximately 24 months)
Presence of out-of-range biological test results (Stage 1)
Number of participants with out-of-range biological tests
Time frame: Up to 7 days after primary vaccination
Presence of out-of-range biological test results (Stage 2 Booster Cohort)
Number of participants with out-of-range biological tests
Time frame: Up to 7 days after booster vaccination
hMPV A serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main Cohorts
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)
hMPV B serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main Cohorts
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)
RSV A serum nAb titers in Stage 1 Sentinel and Main Cohorts
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)
RSV B serum nAb titers in Stage 1 Sentinel and Main Cohorts
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)
hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)
hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)
RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)
RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)
hMPV serum anti-F immunoglobulin G (IgG) antibody (Ab) titers (Stage 1)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01) and 28 days (D29) post-primary vaccination
RSV serum anti-F IgG Ab titers (Stage 1)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01) and 28 days (D29) post-primary vaccination
hMPV A serum nAb titers (Stage 2 Expansion Cohort)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination
hMPV B serum nAb titers (Stage 2 Expansion Cohort)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination
hMPV A serum anti-F IgG Ab titers (Stage 2 Expansion Cohort)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination
RSV A serum nAb titers (Stage 2 Expansion Cohort)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination
RSV B serum nAb titers (Stage 2 Expansion Cohort)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination
RSV serum anti-F IgG Ab titers (Stage 2 Expansion Cohort)
Ab titers expressed as geometric mean titers (GMTs)
Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.
Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 26 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →
Sanofi Pasteur, a Sanofi Company →